According to new data of a new experimental anti -diabetes pill, orflipron, a phase 3 testing, popular injectable GLP -1, such as ozmpic, appears to be good as drugs.

The study, part of a large clinical trial called Achieve-1, saw how well it works in people with a time-din table type 2 diabetes who were not able to control their blood sugar with diet and alone exercise.

Unlike most diabetic drugs in the GLP-1 category, usually given as injections, Orforglipron is an oral pill that can be taken without any food or water restriction.

It belongs to a group of drugs known as GLP-1 receptor agonist, which helps control blood sugar levels and can also help in weight loss.

After 40 weeks, people taking orflipron saw a significant decline in their HBA1C levels. HBA1C is a blood test showing average blood sugar level in the last 2-3 months.

For most patients, their HBA1C fell from 1.3% to 1.6%, which is a meaningful improvement. Many participants also achieved the level of targeted blood sugar recommended by doctors.

One of the additional benefits of Orforglipron was weight loss. At high doses, people lost an average of 7.3 kg, a bonus for several with type 2 diabetes that struggle with weight management.

The most common side effects were related to the stomach, such as nausea, diarrhea and constipation, but they were mostly mild and had early in treatment.

The pill had a safety profile similar to the existing GLP-1 injected drugs.

The US Medicine Company Elli Lily, who has developed the drug, says it will continue testing orforglipron in more people and expects to present it for approval as a treatment for diabetes and weight management in the coming years.

If approved, it can provide a convenient and effective option for those who prefer pills on injections in the management of type 2 diabetes.